{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Senti Bio (\"Senti\"), located in South San Francisco, CA.","action":"Notice","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2020/12/28/2020-28569.html","cfr_references":[],"citation":"85 FR 84356","comment_url":null,"comments_close_on":"2021-01-12","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 12, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2020-28569","effective_on":null,"end_page":84357,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2020/12/28/2020-28569.xml","html_url":"https://www.federalregister.gov/documents/2020/12/28/2020-28569/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-chimeric","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2020-28569?publication_date=2020-12-28","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2020-12-28/2020-28569/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":202,"last_updated":"2026-06-23 22:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2020-12-28/pdf/2020-28569.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2020-28569.pdf?1608731136","publication_date":"2020-12-28","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2020/12/28/2020-28569.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T18:12:54Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":84356,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors","toc_doc":"Development and Commercialization of Chimeric Antigen Receptor Therapies for the Treatment of FMS-like tyrosine kinase 3 Expressing Malignancies Using Natural Killer Cells Transduced With Retroviral or Lentiviral Vectors","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":85}